In the EPIC-HF trial, a patient-activation tool which was delivered electronically prior to a cardiology clinic visit improved clinician intensification of guideline-directed medical therapies in nearly half of heart failure with reduced ejection fraction (HFrEF) patients.
The hypothesis of the EPIC-HF trial (NCT03334188) was that the use of guideline-directed medical therapies could be improved by encouraging patients to engage providers in prescribing decisions. Prof. Larry Allen (University of Colorado School of Medicine, USA) presented the results of the trial, in which 290 HFrEF patients were randomised 1:1 to receive usual care or additional patient-engagement and education tools [1,2]. These tools consisted of a 3-minute video and a 1-page medication checklist, delivered electronically 1 week, 3 days, and 24 hours prior to a visit at a cardiology clinic. The...
Please login to read the full text of the article.
If you have no account yet, please register now.
« MPN disease burden, quality of life, and treatment patterns Next Article
Anti-CD19 CAR T-cell therapy in relapsed/refractory indolent NHL »